Washington University

Arizona State University

University of Florida Research Foundation, Incorporated

Research, Incorporated

Avant Immunotherapeutics, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Research Corporation Technologies, Inc.

Roy Curtiss, Iii

Shifeng Wang

Soo-Young Wanda

Wei Kong

Steven A Tinge

Kenneth Roland

Cheryl Anne Nickerson

Guy A Cardineau

Wei Sun

Sandra M Kelly

Qingke Kong

Karen Brenneman

Xinyao Liu

Bereket Zekarias

Melha Mellata

Wei Xin

Zhaoxing Shi

Christine Branger

Xiangmin Zhang

Ho Young Kang

Javier Santander-Morales

Banikalyan Swain

Huoying Shi

Jorge Galan

Kenneth S Tung

Javier Santander

Bacterial pathogens have evolved means to succeed as pathogens by infecting without recognition by receptors triggering innate immunity, by suppressing induction of immunity and by inducing immune responses to antigens that confer no protectives immunity. Embodiments described herein circumvent these abilities inso as to provide a vector system that induces maximal protective immune responses. Another major problem in using live attenuated bacterial vaccine vectors is the accumulation of attenuating mutations that confer a virulence and safety but which decrease the ability of the vaccine to invade cells in the MALT to colonize and persist in internal effector lymphoid tissues. The embodiments disclosed herein solve this problem in multiple ways by using regulated delayed in vivo shut off of virulence genes, regulated delayed synthesis of recombinant protective antigens and regulated delayed lysis in vivo to confer biological containment with no persistence of vaccine cells and no survival if excreted.

Protective immunity enhancedvaccine (PIESV) againstspp

Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is aspp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.

Live self-destructing bacterial adjuvants to enhance induction of immunity

The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Induction of protective immunity against antigens

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation, regulated expression of one or more antigens of interest, and/or N-glycan modification of secreted/surface antigens.

Food safety vaccine to controland reducein poultry

Disclosed herein are nucleic acids, vector systems, and vaccines for vaccinating fresh water and marine fish using(Ich) i-antigens. In particular, a recombinant attenuatedvaccine (RAEV) vector system is disclosed with regulated delayed attenuation and regulated delayed lysis in vivo attributes that synthesizes Ich protective antigens to enable vaccination of fresh water and marine fish species susceptible to white spot disease. This vaccine construct is designed to exhibit the invasive properties of virulentat the time of bath immunization and then is programmed to gradually lose virulence attributes and to synthesize protective antigens as a consequence of in vivo cell division as the RAEV colonizes internal effector lymphoid tissues. The ultimate lysis in vivo delivers a bolus of protective antigen along with immunostimulatory molecules to exhibit complete biological containment with no potential for survival in vivo or ex vivo.

Ichthyophthirius multifiliis vaccine system

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens fromas vaccines to prevent necrotic enteritis (NE).

The subject application provides a genetically modified recombinant facultative intracellular invasive bacterial pathogen (RFIIBP) or a recombinant attenuatedvaccine (RASV) strains encoding Zika virus (ZIKV) antigens. These strains exhibit high immunogenicity, complete safety, and attenuation, and are unable to persist or be shed in an infective or viable form. These RFIIBPs and RASVs also exhibit regulated delayed attenuation in vivo, regulated delayed in vivo synthesis of protective ZIKV antigens. Methods of inducing mucosal, systemic and cellular immunities in hosts are also provided and antibodies produced using the disclosed RFIIBPs and RASVs can comprise neutralizing antibodies against ZIKV that do not crossreact with Dengue virus (DENV).

Protective anti-ZIKV vaccine without inducing cross-reactions with dengue

Food safety vaccine to controland reduce campylobacter in poultry

Recombinant attenuatedmutants have been created that show efficacy as oral vaccines against plague caused byand Yersinosis caused by bothand. Thus, live attenuated-based vaccines can be used to prevent Yersinosis in farm animals such as swine, cattle and sheep. The palatable baits containing live attenuated-based vaccines may be acceptable methods to control plague epidemics in wild animals. The methods disclosed can also be used to generate recombinant attenuatedandvaccine strains.

[object Object]

A recombinant bacterium capable of reducing tumor growth is provided, wherein said recombinant bacterium is capable of: a. increased expression of a nucleic acid encoding a chemoreceptor that directs chemotaxis towards tumors, b. accumulation in a quiescent tumor, c. hyper-invasion of a tumor, d. reduced fitness in normal tissue, e. enhanced stimulation of the host innate immune responses, f. delivering a tumor specific DNA vaccine vector to a tumor cell, and g. increased bacterium-induced host programmed cell death.

Recombinant bacterium to decrease tumor growth

Growing community of inventors

Paradise Valley, AZ, United States of America

Roy Curtiss, Iii